COPD: Journal of Chronic Obstructive Pulmonary Disease

PAOG Takes Major CBD Pharmaceutical Development Step Forward

Retrieved on: 
Tuesday, January 5, 2021

Sandusky, Ohio--(Newsfile Corp. - January 5, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced a major step forward in the development of a CBD pharmaceutical product.

Key Points: 
  • Sandusky, Ohio--(Newsfile Corp. - January 5, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced a major step forward in the development of a CBD pharmaceutical product.
  • PAOG today announced an engagement with Veristat, Inc., a contract research organization headquartered in Southborough, Massachusetts.
  • PAOG has engaged Veristat to assist in advancing PAOG with its proprietary Cannabidiol (CBD) extract for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) toward initiating an Investigational New Drug application (IND) with the Food and Drug Administration (FDA).
  • With more than 26 years' experience in clinical trial planning and execution, Veristat is equipped to support any development program.

Franciosi Consulting Assessing New Potential Treatments for Asthma and COPD

Retrieved on: 
Tuesday, December 29, 2020

VANCOUVER, British Columbia, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Lui Franciosi is pleased to announce that Franciosi Consulting Ltd. will be assessing the use of glycosaminoglycans (GAGs) for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD).

Key Points: 
  • VANCOUVER, British Columbia, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Lui Franciosi is pleased to announce that Franciosi Consulting Ltd. will be assessing the use of glycosaminoglycans (GAGs) for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD).
  • The use of inhaled unfractionated heparin has been shown to have anti-inflammatory and mucolytic effects with the potential to modify the progression of asthma and COPD.
  • For more information about Lui Franciosi and his company Franciosi Consulting Ltd., please visit https://franciosiconsulting.com/ or his YouTube Channel https://www.youtube.com/channel/UC7PSoeH8yN-HuLg5xFi5Qxw/ .
  • Lui Franciosi founded Franciosi Consulting Ltd. in 2015 and is the president and CEO.

vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer’s Disease and Type 2 Diabetes

Retrieved on: 
Tuesday, December 15, 2020

The 6-month trial investigated the efficacy and safety of 5 mg azeliragon administered orally once daily compared to placebo in 43 people with mild probable Alzheimers disease and type 2 diabetes.

Key Points: 
  • The 6-month trial investigated the efficacy and safety of 5 mg azeliragon administered orally once daily compared to placebo in 43 people with mild probable Alzheimers disease and type 2 diabetes.
  • The azeliragon treated group (n=21) had a 1.8 point decline from baseline in ADAS-cog14 compared to a placebo (n=22) decline of 0.35.
  • vTv has a pipeline of clinical drug candidates led by programs for the treatment of type 1 diabetes, Alzheimers and related dementia, and inflammatory disorders.
  • vTvs development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease (COPD), genetic mitochondrial diseases, and chronic kidney disease.

COPD Foundation and Blue Marble Health enter a Strategic Partnership to Promote Virtual Pulmonary Rehabilitation to healthcare systems challenged to deliver services during COVID

Retrieved on: 
Tuesday, December 1, 2020

MIAMI and LOS ANGELES, Dec. 1, 2020 /PRNewswire/ --The COPD Foundation and Blue Marble Health announced a strategic Partnership to increase availability and adherence to pulmonary rehabilitation (PR) through a unique peer supported Virtual PR Program.

Key Points: 
  • MIAMI and LOS ANGELES, Dec. 1, 2020 /PRNewswire/ --The COPD Foundation and Blue Marble Health announced a strategic Partnership to increase availability and adherence to pulmonary rehabilitation (PR) through a unique peer supported Virtual PR Program.
  • Blue Marble Health Virtual PR Platform enables clinicians to remotely develop, monitor, and track personalized PR programs at the individual and population level.
  • The Blue Marble Health ( www.BlueMarbleHealthCo.com ) Assessment, Intervention, Monitoring and Analytics Platform supports onsite and home-based Telehealth and Care Management for COPD, and other chronic conditions.
  • The COPD Foundation is a 501(c)(3) not-for-profit organization created in 2004, with offices in Washington, D.C. and Miami, FL.

Chronic Obstructive Pulmonary Disease (COPD) Pipeline Review, H2 2020 - Therapeutic Analysis Report Featuring 50+ Companies - ResearchAndMarkets.com

Retrieved on: 
Monday, November 23, 2020

Chronic Obstructive Pulmonary Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Key Points: 
  • Chronic Obstructive Pulmonary Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • The Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects.
  • The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics and enlists all their major and minor projects.

Now Recruiting Patients for a New FDA Oversight Trial Evaluating the Use of a Patient's Own Fat Tissue for the Treatment of Post-COVID-19 Lung Damage

Retrieved on: 
Tuesday, November 17, 2020

Robert W. Alexander, MD, DMD, FICS is the Principal Investigator, and his office is recruiting patients for enrollment in the trial.

Key Points: 
  • Robert W. Alexander, MD, DMD, FICS is the Principal Investigator, and his office is recruiting patients for enrollment in the trial.
  • "We're building on two years of existing trials in patients suffering from Chronic Obstructive Pulmonary Disease (COPD) and Farmer's Lung Disease (FLD)," says Dr. Robert W. Alexander, MD, DMD, FICS.
  • Many of these patients, who have been told to get their affairs in order, experience improved lung function and quality of life after treatment.
  • Patients considering participation in this clinical trial should email Dr. Alexander at [email protected] .

CSA Medical Announces Enrollment Milestone in a Mechanism of Action Study utilizing the RejuvenAir® System for COPD Patients with Chronic Bronchitis

Retrieved on: 
Wednesday, November 11, 2020

BOSTON, Nov. 11, 2020 /PRNewswire/ -- CSA Medical, Inc., today announcedthat over half of the subjects in a 32 patient study, characterizing the mechanism of action of Metered Cryospray (MCS) with the RejuvenAir System in patients with Chronic Bronchitis, have been enrolled.

Key Points: 
  • BOSTON, Nov. 11, 2020 /PRNewswire/ -- CSA Medical, Inc., today announcedthat over half of the subjects in a 32 patient study, characterizing the mechanism of action of Metered Cryospray (MCS) with the RejuvenAir System in patients with Chronic Bronchitis, have been enrolled.
  • "We know from the feasibility study that patients achieved meaningful improvementsintheir cough and overall quality of life.
  • This study will provide a cellular rationale for the remodeling response observed after metered cryospray and clinical improvements identified in the previous study."
  • Chronic Bronchitis is the largest disease subset of Chronic Obstructive Pulmonary Disease (COPD).

Europe Airway Clearance System Market to 2025 - by Type, Application, End-use, and Country - ResearchAndMarkets.com

Retrieved on: 
Monday, November 9, 2020

The "Europe Airway Clearance System Market, by Type, by Application, by End Use, by Country, Industry Analysis and Forecast, 2019 - 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Airway Clearance System Market, by Type, by Application, by End Use, by Country, Industry Analysis and Forecast, 2019 - 2025" report has been added to ResearchAndMarkets.com's offering.
  • The airway clearance systems market is very competitive and has the involvement of Tier 1 and Tier 2 companies as well as many small businesses.
  • The growing adoption of airway clearance systems for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and chronic bronchitis drives market growth.
  • Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

Philips expands its home care portfolio for COPD patients with first-of-its-kind non-invasive ventilator

Retrieved on: 
Wednesday, November 4, 2020

With the introduction of this non-invasive ventilator, Philips extends its homecare solutions with a new ventilation therapy feature for chronic obstructive pulmonary disease (COPD) patients to breathe easier.

Key Points: 
  • With the introduction of this non-invasive ventilator, Philips extends its homecare solutions with a new ventilation therapy feature for chronic obstructive pulmonary disease (COPD) patients to breathe easier.
  • EFL often goes undetected, meaning patients dont receive the care they need to improve their disease, said Eli Diacopoulos, Respiratory Care Business Leader at Philips.
  • Clinicians can now detect EFL in hypercapnic COPD patients at the point of care, ensure personalized patient treatment at home and monitor care remotely.
  • When prescribed and used in the home, the BiPAP A40 EFL connects to Philips Care Orchestrator cloud-based care management system.

PAOG Announces CRO Agreement To Advance Respiratory Cannabis Treatment Through Regulatory Approval

Retrieved on: 
Friday, October 23, 2020

PAOG signed the agreement yesterday, prior to the comprehensive corporate update scheduled for publication today and included in its entirety below.

Key Points: 
  • PAOG signed the agreement yesterday, prior to the comprehensive corporate update scheduled for publication today and included in its entirety below.
  • Less than ninety days ago, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY) and began to transform the company into cannabis biopharmaceutical development operation.
  • RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD) derived from a patented cannabis extraction method- U.S. Patent No.
  • The CRO agreement signed yesterday is a year long agreement and a major step forward to advancing RespRx through the regulatory approval process.